New approaches to target the androgen receptor and STAT3 for prostate cancer treatments

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 3, 2009, Pages 395-400

  He, Meilan ^a   Young, Charles Y F ^a  

^a MAYO CLINIC   (United States)

Author keywords

Androgen receptor; AR chaperones; Domain; Small molecule inhibitor; STAT3

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BICALUTAMIDE; CUCURBITACIN; CURCUMIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE INHIBITOR; INDIRUBICIN; LENTIVIRUS VECTOR; LYASE INHIBITOR; OGX 427; PACLITAXEL; RESVERATROL; STA 21; STAT3 PROTEIN; STATTIC; STEROID 5ALPHA REDUCTASE INHIBITOR; TANESPIMYCIN; UNCLASSIFIED DRUG; AR PROTEIN, HUMAN; CHAPERONE; STAT3 PROTEIN, HUMAN;

ANTIANDROGEN THERAPY; APOPTOSIS; CANCER GENE THERAPY; CANCER INHIBITION; CANCER THERAPY; CHROMOSOME XQ; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPETITIVE INHIBITION; DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; REVIEW; TRANSACTIVATION; TRANSCRIPTION INITIATION; VIRAL GENE DELIVERY SYSTEM; CHEMICAL STRUCTURE; DRUG ANTAGONISM; MALE; METABOLISM; PROSTATE TUMOR;

CLINICAL TRIALS AS TOPIC; HUMANS; MALE; MOLECULAR CHAPERONES; MOLECULAR STRUCTURE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STAT3 TRANSCRIPTION FACTOR;

EID: 65349191756     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389557510909030395     Document Type: Review

References (74)

1. Grossmann, M.E.; Huang, H.; Tindall, D.J. Androgen receptor signaling in androgen refractory prostate cancer. J. Nat. Cancer Institute, 2001, 93, 1687-97.
2. Jose, D.D.; Donald, J.T. Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med., 2004, 351, 1488-90.
3. Culig, Z. Interleukin-6 polymorphism: expression and pleiotropic regulation in human prostate cancer. J. Urol., 2005, 174, 417-23.
4. Taplin, M.E. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat. Clin. Pract. Oncol., 2007, 4, 236-44.
5. Gignac, G.A.; Morris, M.J.; Hussain, M. Castration resistant, taxane naïve metastatic prostate cancer: current clinical approaches and future directions. J. Urol., 2007, 178, S30-5.
6. Wallner, L.D.J.; Escara-Wilke, J.; Zhang, J. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res., 2006, 66, 3087-94.
7. Drachenberg, D.E.; Elgamal, A.A.; Rowbotham, R. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate, 1999, 41, 127-34.
8. Okamoto, M.; Lee, C.; Oyasu, R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res., 1997, 57, 141-50.
9. Lee, S.O.; Lou, W.; Johnson, C.S. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate, 2004, 60, 178-184.
10. Abdulghani, J.; Gu, L.; Dagvadorj, A.; Lutz, J. Stat3 promotes metastatic progression of prostate cancer. Am. J. Pathol., 2008, 172, 1717-23.
11. Tam, L.; McGlynn, L.M.; Traynor, P. Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br. J. Cancer, 2007, 97, 378-87.
12. Wang, T.; Niu, G., Kortylewski, M. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med., 2004, 10, 48-56.
13. Löffler, D.; Brocke-Heidrich, K.; Pfeifer, G.Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood, 2007, 110, 1330-3.
14. Cabrespine, A.; Bay, J.O.; Verrelle, P.; Morel, L. Interleukin-6 implication in prostate cancer. Bull. Cancer, 2007, 94, F29-32.
15. Aaronson, D.S.; Muller, M.; Neves, S.R. An androgen-IL6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells. Mol. Cell Endocrinol., 2007, 270, 50-56.
16. Li, J.; Fu, J.; Toumazou, C.; Yoon, H.G. A role of the aminoterminal (N) and carboxyl- terminal (C) interaction in binding of androgen receptor to chromatin. Mol. Endocrinol., 2006, 20, 776-81.
17. Shang, Y.; Myers, M.; Brown, M. Formation of the androgen receptor transcription complex. Mol. Cell, 2002, 9, 601-8.
18. Dehm, S.M.; Tindall, D.J. Molecular regulation of androgen action in prostate cancer. J. Cell. Biochem., 2006, 99, 333-41.
19. Dehm, S.M.; Tindall, D.J. Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J. Biol. Chem., 2006, 281, 27882-90.
20. Dehm, S.M., Regan, K.M.; Schmidt, L.J. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells. Cancer Res., 2007, 67, 10067-76.
21. Libertini, S.J.; Tepper, C.G.; Rodriguez, V. Evidence for calpainmediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res., 2007, 67, 9001-9.
22. Rios-Doria, J., Day, K.C.; Kuefer, R. The role of calpain in the proteolytic cleavage of E- cadherin in prostate and mammary epithelial cells. J. Biol. Chem., 2003, 278, 1372-81.
23. Blaszczyk, N.; Masri, B.A.; Mawji, N.R. Osteoblast-derived factors induce androgen- independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin. Cancer Res., 2004, 10, 1860-71.
24. Ueda, T.; Bruchovsky, N.; Sadar, M.D. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem., 2002, 77, 7076-87.
25. Wang, G.; Sadar, M.D. Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer. J. Cell Biochem., 2006, 98, 36-44.
26. Ping, Z.; Sung, H.B.; Eliot, M.B. Macrophage/Cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell, 2006, 124, 615-27.
27. Ueda, T.; Mawji, N.R.; Bruchovsky, N. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J. Biol. Chem., 2002, 277, 38087-98.
28. Quayle, S.N.; Mawji, N.R.; Wang, J. Androgen receptor decoy molecules block the growth of prostate cancer. Proc. Natl. Acad. Sci. USA, 2007, 104, 1331-42.
29. Schaufele, F.; Carbonell, X.; Guerbadot, M. The structural basis of androgen receptor activation: Intramolecular and intermolecular amino-carboxy interactions. Proc. Natl. Acad. Sci. USA, 2005, 102, 9802-11.
30. Edwards, J.; Bartlett, J.M. The androgen receptor and signaltransduction pathways in hormone- refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU Int., 2005, 95, 1327-36.
31. Tyagi, R.K.; Lavrovsky, Y.; Ahn, S.C. Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol. Endocrinol., 2000, 14, 1162-71.
32. Shatkina, L.; Mink, S.; Rogatsch, H. The cochaperone Bag-1L enhances androgen receptor action via interaction with the NH2-terminal region of the receptor. Mol. Cell Biol., 2003, 23, 7189-98.
33. Cheung-Flynn, J.; Prapapanich, V.; Cox, M.B. Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Mol. Endocrinol., 2005, 19, 1654-66.
34. Singh, P.; Hallur, G.; Anchoori, R.K.; Bakare, O. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer. Prostate, 2008, 21, 467-73.
35. Zhou, Z.X.; Sar, M.; Simental, J.A. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. J. Biol. Chem., 1994, 269, 13115-23.
36. Saporita, A.J.; Zhang, Q.; Navai, N. Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor. J. Biol. Chem., 2003, 278, 41998-2006.
37. Chen, C.D.; Welsbie, D.S.; Tran, C. Molecular determinants of resistance to antiandrogen Therapy. Nat. Med., 2004, 10, 33-45.
38. Anthony, J.S.; Junkui, A.; Zhou, W. The Hsp90 Inhibitor, 17-AAG, Prevents the Ligand- Independent Nuclear Localization of Androgen Receptor in Refractory Prostate Cancer Cells. Prostate, 2007, 67, 509-21.
39. Pratt, W.B.; Toft, D.O. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr. Rev., 1997, 18, 306-13.
40. DeFranco, D.B.; Ramakrishnan, C.; Tang, Y. Molecular chaperones and subcellular trafficking of steroid receptors. J. Steroid. Biochem. Mol. Biol., 1998, 65, 51-62.
41. Solit, D.Hsp90 as a therapeutic target in prostate cancer. Semin. Oncol., 2003, 30, 709-15.
42. Banerji, U. Phase I pharmacokinetic and pharmacodynamic study of 17-Allylmino, 17- demethoxy geldannmycin in patients with advanced malignancies. J. Clin. Oncol., 2005, 23, 4152-64.
43. Goetz, M.P. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J. Clin. Oncol., 2005, 23, 1078-89.
44. Grem, J. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J. Clin. Oncol., 2005, 23, 1885-97.
45. Rocchi, P.; Beraldi, E.; Ettinger, S. Increased Hsp27 after androgen ablation facilitates androgen Independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res., 2005, 65, 11083-92.
46. Rocchi, P.; So, A.; Kojima, S. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res., 2004, 64, 6595-603.
47. Mendelsohn, M.E.; Zhu, Y.; O'Neil, S. The 29-kDa proteins phosphorylated in thrombin- activated human platelets are forms of the estrogen receptor-related 27-kDa heat shock protein. Proc. Natl. Acad. Sci. USA, 1991, 88, 11212-21.
48. Song, H.; Ethier, S.P.; Dziubinski, M.L. Stat3 modulates heat shock 27 kDa protein expression in breast epithelial cells. Biochem. Biophys. Res. Commun., 2004, 314, 143-54.
49. Cha, T.L.; Qiu, L.; Chen, C.T. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res., 2005, 65, 2287-98.
50. Gaughan, L.; Logan, I.R.; Neal, D.E. Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids. Res., 2005, 33, 13-21.
51. Niu, G.; Heller, R.; Catlett-Falcone, R. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res., 1999, 59, 5059-64.
52. Lewis, H.D.; Winter, A.; Murphy, T.F.; Tripathi, S.; Pandey, V.N.; Barton, B.E.. STAT3 inhibition in prostate and pancreatic cancer lines by STAT3 binding sequence oligonucleotides: differential activity between 5′ and 3′ ends. Mol. Cancer Ther., 2008, 7, 1543-52.
53. Xi, S.; Gooding, W.E.; Grandis, J.R. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene, 2005, 24, 970-9.
54. Leong, P.L.; Andrews, G.A.; Johnson, D.E. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc. Natl. Acad. Sci. USA, 2003, 138, 4143-50.
55. Barton, B.E.; Murphy, T.F.; Shu, P. Novel single-stranded Oli-gonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. Mol. Cancer Ther., 2004, 3, 1183-92.
56. Konnikova, L.; Kotecki, M.; Kruger, M.M. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer, 2003, 3, 23-30.
57. Ling, X.; Arlinghaus, R.B. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res., 2005, 65, 2532-41.
58. Gao, L.; Zhang, L.; Hu, J.; Li, F. Down-Regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin. Cancer Res., 2005, 11, 6333-42.
59. Weerasinghe, P.; Li, Y.; Guan, Y.; Zhang, R.; Tweardy, D.J.; Jing, N.. T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling. Prostate, 2008, 68, 1430-9.
60. Aggarwal, B.B.; Kumar, A.; Bharti, A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res., 2003, 23, 363-71.
61. Sun, J.; Blaskovich, M.A.; Jove, R. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene, 2005, 24, 3236-43.
62. Xiao, Z.; Hao, Y.; Liu, B. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk. Lymphoma, 2002, 43, 1763-72.
63. Deng, J.; Grande, F.; Neamati, N. Small molecule inhibitors of Stat3 signaling pathway. Curr. Cancer Drug Targets, 2007, 7, 91-9.
64. Nam, S.; Buettner, R.; Turkson, J. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc. Natl. Acad. Sci. USA, 2005, 102, 5998-605.
65. Kotha, A.; Sekharam, M.; Cilenti, L. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol. Cancer Ther., 2006, 5, 621-9.
66. Coleman, D.R.; Ren, Z.; Mandal, P.K. Investigation of the binding determinants of phosphopeptides targeted to the Src homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor. J. Med. Chem., 2005, 48, 6661-72
67. Siddiquee, K.; Zhang, S.; Guida, W.C.; Blaskovich, M.A.; Greedy, Greedy, B.; Lawrence, H.R.; Yip, M.L.; Jove, R. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. USA, 2007, 104, 7391-402.
68. Song, H.; Wang, R., Wang, S. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. USA, 2005, 102, 4700-12.
69. Schust, J.; Sperl, B.; Hollis, A. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol., 2006, 13, 1235-42.
70. Muthian, G.; Bright, J.J. Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte. J. Clin. Immunol., 2004, 24, 542-55.
71. Nakamura, K.; Yasunaga, Y.; Segawa, T. Curcumin downregulates AR gene expression and activation in prostate cancer cell lines. Int. J. Oncol., 2002, 21, 825-33.
72. Xing. N.; Chen, Y.; Mitchell, S.H. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis, 2001, 22, 409-18.
73. Lang, S.A.; Moser, C.; Gaumann, A. Targeting Heat Shock Protein 90 in Pancreatic Cancer Impairs Insulin-like Growth Factor-I Receptor Signaling, Disrupts an Interleukin-6/Signal- Transducer and Activator of Transcription 3/Hypoxia-Inducible Factor-1{alpha} Autocrine Loop, and Reduces Orthotopic Tumor Growth. Clin. Cancer Res., 2007, 13, 6459-67.
74. Zhou, J.; Wulfkuhle, J.; Zhang, H. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. USA, 2007, 104, 16158-164.